AMPH · XBRL financial data

Amphastar Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AMPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	181	178*	172	182	191	187*	171	174	192	183*	171	184
Cost of revenue	72	82*	82	87	89	100*	85	88	93	97*	101	90
Gross profit	108	96*	90	95	102	87*	85	86	99	86*	70	93
Research and development	17	20*	17	18	21	18*	20	20	22	23*	27	22
General and administrative	13	13*	16	13	15	13*	16	14	39	16*	18	18
Total operating expenses	36	42*	42	40	45	42*	48	44	73	50*	57	54
Operating income (loss)	73	54*	48	55	57	45*	37	42	25	36*	14	40
Interest income	1	2*	3	3	2	2*	2	2	2	2*	2	2
Interest expense	14	9*	9	9	7	6*	6	6	6	7*	7	7
Other income (expense)	3	(5)*	6	0	(5)	3*	(2)	2	0	1*	1	3
Income tax expense (benefit)	14	5*	4	12	7	6*	6	8	4	7*	4	8
Net income (loss)	49	36*	43	38	40	38*	25	31	17	24*	6	30
Earnings per share, basic USD per share	1.01	0.75*	0.90	0.77	0.83	0.79*	0.53	0.66	0.38	0.53*	0.14	0.69
Earnings per share, diluted USD per share	0.91	0.68*	0.81	0.73	0.78	0.74*	0.51	0.64	0.37	0.52*	0.14	0.67
Weighted average shares, basic millions of shares	49	48*	48	49	49	48*	48	47	46	46*	45	44
Weighted average shares, diluted millions of shares	54	53*	53	52	52	51*	50	48	48	47*	46	44

Fiscal quarters (AMPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	267	144	201	190	192	152	183	188	216	170	171	224
Short-term investments	33	113	88	28	58	70	54	44	60	113	121	67
Accounts receivable	119	115	138	131	140	136	145	133	147	144	148	145
Inventory	110	106	115	122	130	154	185	192	186	177	170	180
Prepaid and other current assets	6	9	9	8	18	18	18	20	26	13	12	11
Total current assets	543	490	555	483	546	534	588	581	639	636	634	631
Property and equipment, net	281	283	289	288	295	297	308	310	309	311	307	316
Right-of-use asset	33	32	31	32	32	47	46	44	45	43	71	73
Goodwill	3	3	3	3	3	3	3	3	3	3	3	3
Total assets	1,545	1,513	1,574	1,492	1,545	1,577	1,626	1,615	1,666	1,629	1,648	1,744
Accounts payable	32	25	37	32	34	31	53	42	41	33	36	29
Accrued liabilities	191	68	80	99	119	127	123	125	150	116	117	222
Total current liabilities	258	225	255	137	159	174	199	176	205	158	164	263
Long-term debt	653	603	—	—	—	614	—	—	—	620	—	—
Lease liability, non-current	30	30	29	29	29	42	41	39	39	38	65	67
Total liabilities	949	873	902	778	818	845	875	858	889	840	875	976
Retained earnings	373	409	452	490	531	569	594	625	642	667	673	704
Total liabilities and equity	1,545	1,513	1,574	1,492	1,545	1,577	1,626	1,615	1,666	1,629	1,648	1,744
Common shares outstanding (cover page) millions of shares	48	48	49	49	48	48	47	46	46	45	44	43

Fiscal quarters (AMPH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	49	36*	43	38	40	38*	25	31	17	24*	6	30
Stock-based compensation	5*	5*	7	6*	6*	6*	8	6*	6*	6*	9	7*
Depreciation and amortization	10	10*	10	10	10	—	—	15	14	—	—	14
Net cash from operating activities	64*	24*	55	69*	60*	29*	35	36*	53*	33*	48	51*
Purchases of property and equipment	10*	9*	9	6*	14*	12*	11	11*	5*	8*	10	9*
Net cash from investing activities	(31)*	(103)*	15	(70)*	(35)*	(36)*	10	(1)*	(20)*	(61)*	(17)	45*
Share repurchases	50*	0*	—	—	35*	42*	11	39*	5*	21*	29	45*
Proceeds from long-term debt	345*	0*	—	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	200*	50*	0	8*	0*	0*	0	0*	0*	0*	0	0*
Net cash from financing activities	87*	(47)*	(14)	(11)*	(23)*	(34)*	(15)	(30)*	(4)*	(18)*	(30)	(44)*
Net change in cash	120*	(127)*	57	(12)*	2*	(41)*	31	5*	29*	(46)*	1	53*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Amphastar Pharmaceuticals	224	184	51*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Stoke Therapeutics	107	11	(63)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Evolus	45	84	(3.6)*	66.1M	12.6 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	45	51	(56)*	74.4M	6.8 quarters	Q2 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.